Biocept Inc (NASDAQ:BIOC) (FRA:B003) CEO Mike Nall, CFO Tim Kennedy, and Chief Medical Officer Dr Michael Dugan joined Proactive to discuss the group's third-quarter results that saw its revenue jump four-fold year-over-year, driven by the molecular diagnostics company’s astute decision to offer coronavirus (COVID-19) RT-PCR testing.
The trio say offering COVID-19 testing services was the right thing to do, and fully expect this testing to be an important part of the business until the pandemic subsides. Nall adds oncology is still a long-term focus as it continues to build its business for a post-pandemic future.
